Calendario›REGN›Cemiplimab

Cemiplimab

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Cancer de pulmon no microcitico.

Más ensayos de: Cáncer de pulmón no microcítico.

Fase

Fase 2

Estado

En marcha, sin reclutar

Participantes

120

previstos

Centros

47

Fin del objetivo primario

may 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en nov 2024.

Qué mide

Major pathologic response (MPR) rate as determined by central blinded independent pathology review (BIPR) (del registro, en inglés) (hasta 12 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06465329), actualizada en ago 2026.